Publications by authors named "P Vela"
Anaplastic thyroid cancer (ATC) is a clinically aggressive malignancy with a dismal prognosis. Combined BRAF/MEK inhibition offers significant therapeutic benefit in patients with -mutant ATCs. However, relapses are common and overall survival remains poor.
View Article and Find Full Text PDFSince the last century, it has been shown that dedifferentiated cells of can produce catechins and other secondary metabolites under in vitro conditions, with potential applications in the cosmetic, pharmaceutical and food industries. In this work, cell suspension cultures of a cell line (LSC-5Y) were established in a liquid medium in order to optimize the biomass productivity, catechin monomer (GC, EGC, C, EC, CG, and ECG) and alkaloid (TB and CAF) productivity. The following factors were evaluated: concentration of growth regulators (BA and IBA), inoculum size, age of the cell line, light exposure, and effect of biotic elicitors (MeJA and extracts of ).
View Article and Find Full Text PDFObjective: To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort.
Methods: Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).
Article Synopsis
- * Out of 196 patients treated with TCZ, a significant percentage achieved clinical remission within six months, but imaging improvements lagged behind, with only 12% showing imaging remission at that time.
- * Despite initial concerns, no new aneurysms developed in patients on TCZ therapy during the follow-up, indicating its potential as a safe treatment option for GCA-aortitis.
Objective: to investigate the occurrence and relative risk of incident malignancy in patients with rheumatic diseases and previous malignancies treated with biologic and targeted synthetic DMARDs (b/tsDMARDs).
Methods: Cohort study of patients included in BIOBADASER 3.0 up to 2021, treated with b/tsDMARDs and history of a previous malignancy.